Qualigen Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Qualigen Therapeutics generated cash of -$10,304,263, which is more than the previous year. Cash used in financing activities reached the amount of -$550,000 last year. Net change in cash is therefore -$6,638,320.
Cash Flow
| 2014 | -1.15M | -1.16K | 3.45M |
|---|---|---|---|
| 2015 | -5.72M | -16.99K | 18.81M |
| 2016 | -15.20M | -8.06K | 6.44M |
| 2017 | -7.39M | -7.67K | 22.99M |
| 2018 | -13.33M | -6.97M | 5.48M |
| 2020 | 57.33K | -194.47K | 165.14K |
| 2020 | -9.75M | -160.55K | 33.76M |
| 2021 | -14.73M | -141.36K | 8.43M |
| 2022 | -13.24M | -183.76K | 2.91M |
| 2023 | -10.30M | 4.21M | -550K |
QLGN Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 7.04M | 17.53M | 23.97M | 125.12K | 125.12K | 22.63M | 7.04M | 15.81M | 2.74M | 448.22K |
Operating activities | ||||||||||
Net income | -12.47M | -21.03M | -17.89M | -20.41M | -1.78M | -16.86M | -7.86M | -18.38M | -8.78M | -2.47M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 4.49K | 375.60K | 338.27K | 293.36K | 216.60K | 5.7K | 5.7K | 5.20K | 1.93K | 3.47K |
Stock-based compensation expense | 1.09M | 5.48M | 5.29M | 2.80M | 7.86K | 0 | 34.19K | 0 | 2.89M | 0 |
| Deferred income tax benefit | 1.09M | 5.48M | 5.29M | 2.80M | 7.86K | 0 | 34.19K | 0 | 2.89M | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 417.70K | 41.25K | 545.58K | 129.34K | -54.45K | -92.22K | 0 | 0 | 0 |
Inventories | 0 | -637.41K | 111.42K | -326.06K | 57.91K | 288.63K | 223.83K | 0 | 0 | 0 |
Accounts payable | 1.60M | -33.39K | 385.45K | 0 | 482.17K | 3.16M | 341.21K | 1.15M | -344.24K | 0 |
Cash generated by operating activities | -10.30M | -13.24M | -14.73M | -9.75M | 57.33K | -13.33M | -7.39M | -15.20M | -5.72M | -1.15M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 9.43K | 8.82M | 0 | 0 | -6.96M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -319.11K | -141.36K | -210.19K | -194.47K | -2.00K | -7.67K | -8.06K | -16.99K | -1.16K |
Acquisitions Net | 0 | 135.35K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 4.21M | -183.76K | -141.36K | -160.55K | -194.47K | -6.97M | -7.67K | -8.06K | -16.99K | -1.16K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 8.82M | 0 | -49.62B | 6M | 2M | 2.04M | 21.00M | 3.02M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | -3.11M | 0 | -327.56K | 0 |
Repurchases of common stock | 0 | -505 | 0 | 0 | 0 | 0 | 2M | 2.02M | 1M | 0 |
Repayments of term debt | -550K | 2.90M | -138.73K | -165.14K | 165.14K | -1.34M | 0 | 0 | 0 | -573.5K |
Cash used in financing activities | -550K | 2.91M | 8.43M | 33.76M | 165.14K | 5.48M | 22.99M | 6.44M | 18.81M | 3.45M |
Net Change In Cash | -6.63M | -10.49M | -6.43M | 27.99K | 27.99K | -14.81M | 15.58M | -8.77M | 13.07M | 2.29M |
Cash at end of period | 401.80K | 7.04M | 17.53M | 153.12K | 153.12K | 7.81M | 22.63M | 7.04M | 15.81M | 2.74M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |